Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives.

The COVID-19 pandemic has been a challenge for countries and health professionals worldwide. Viral entry by ACE-2 receptor and an excessive activation of the immune system are key to understand both incidence and severity of disease. Inflammatory Bowel Disease (IBD) represents a special condition as...

Descripción completa

Detalles Bibliográficos
Autores: Suria C, Bosca-Watts MM, Navarro P, Tosca J, Anton R, Sanahuja A, Revaliente M, Miguel Minguez M
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:INCLIVA
Repositorio:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p15798
Acceso en línea:https://incliva.portalinvestigacion.com/publicaciones/15798
Access Level:acceso abierto
Palabra clave:COVID-19 grave
COVID-19 incidence
COVID-19 vaccine
Enfermedad inflamatoria intestinal (EII)
IBD-treatment
Incidencia por COVID-19
Inflammatory Bowel Disease (IBD)
Severe COVID-19
Vacuna COVID-19
tratamiento de la EII
id ES_bc3ba8471426873c19bf10ae91e8b787
oai_identifier_str oai:incliva.fundanetsuite.com:p15798
network_acronym_str ES
network_name_str España
repository_id_str
spelling Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives.Suria CBosca-Watts MMNavarro PTosca JAnton RSanahuja ARevaliente MMiguel Minguez MCOVID-19 graveCOVID-19 incidenceCOVID-19 vaccineEnfermedad inflamatoria intestinal (EII)IBD-treatmentIncidencia por COVID-19Inflammatory Bowel Disease (IBD)Severe COVID-19Vacuna COVID-19tratamiento de la EIIThe COVID-19 pandemic has been a challenge for countries and health professionals worldwide. Viral entry by ACE-2 receptor and an excessive activation of the immune system are key to understand both incidence and severity of disease. Inflammatory Bowel Disease (IBD) represents a special condition associated with an inordinate response of the immune system to external agents. IBD treatments have been associated to an increased risk of bacterial and viral infections. This has raised the question of possible higher incidence and severity of COVID-19 infection in IBD patients. Several papers have been published during this year of pandemic to answer that question. Moreover, COVID-19 vaccination offers great promise in controlling infection in patients with IBD. Based on current evidence, patients with IBD do not have a higher incidence of COVID-19 than the general population, and they do not have worse disease evolution. Advanced age and presence of a greater number of comorbidities have been associated with worse outcomes, similar to the general population. Corticosteroids are associated to an increased risk of COVID-19 infection, higher hospitalization rate and higher risk of severe COVID-19. 5-ASA/Sulfasalazine and Thiopurines have a possible increased risk of severe COVID-19, although studies are lacking. On the other hand, Anti-TNF may have a possible protective effect. It is recommended to maintain the treatment. Anti-IL-12/23, anti-integrins and tofacitinib have results comparable to anti-TNF. Based on the efficacy, expert recommendations, and the absence of other evidence, it is recommended that patients with IBD be vaccinated.ELSEVIER ESPANA SLU2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/15798Gastroenterologia y HepatologiaISSN: 02105705reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAEspañolinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p157982026-06-07T16:35:31Z
dc.title.none.fl_str_mv Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives.
title Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives.
spellingShingle Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives.
Suria C
COVID-19 grave
COVID-19 incidence
COVID-19 vaccine
Enfermedad inflamatoria intestinal (EII)
IBD-treatment
Incidencia por COVID-19
Inflammatory Bowel Disease (IBD)
Severe COVID-19
Vacuna COVID-19
tratamiento de la EII
title_short Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives.
title_full Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives.
title_fullStr Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives.
title_full_unstemmed Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives.
title_sort Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives.
dc.creator.none.fl_str_mv Suria C
Bosca-Watts MM
Navarro P
Tosca J
Anton R
Sanahuja A
Revaliente M
Miguel Minguez M
author Suria C
author_facet Suria C
Bosca-Watts MM
Navarro P
Tosca J
Anton R
Sanahuja A
Revaliente M
Miguel Minguez M
author_role author
author2 Bosca-Watts MM
Navarro P
Tosca J
Anton R
Sanahuja A
Revaliente M
Miguel Minguez M
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv COVID-19 grave
COVID-19 incidence
COVID-19 vaccine
Enfermedad inflamatoria intestinal (EII)
IBD-treatment
Incidencia por COVID-19
Inflammatory Bowel Disease (IBD)
Severe COVID-19
Vacuna COVID-19
tratamiento de la EII
topic COVID-19 grave
COVID-19 incidence
COVID-19 vaccine
Enfermedad inflamatoria intestinal (EII)
IBD-treatment
Incidencia por COVID-19
Inflammatory Bowel Disease (IBD)
Severe COVID-19
Vacuna COVID-19
tratamiento de la EII
description The COVID-19 pandemic has been a challenge for countries and health professionals worldwide. Viral entry by ACE-2 receptor and an excessive activation of the immune system are key to understand both incidence and severity of disease. Inflammatory Bowel Disease (IBD) represents a special condition associated with an inordinate response of the immune system to external agents. IBD treatments have been associated to an increased risk of bacterial and viral infections. This has raised the question of possible higher incidence and severity of COVID-19 infection in IBD patients. Several papers have been published during this year of pandemic to answer that question. Moreover, COVID-19 vaccination offers great promise in controlling infection in patients with IBD. Based on current evidence, patients with IBD do not have a higher incidence of COVID-19 than the general population, and they do not have worse disease evolution. Advanced age and presence of a greater number of comorbidities have been associated with worse outcomes, similar to the general population. Corticosteroids are associated to an increased risk of COVID-19 infection, higher hospitalization rate and higher risk of severe COVID-19. 5-ASA/Sulfasalazine and Thiopurines have a possible increased risk of severe COVID-19, although studies are lacking. On the other hand, Anti-TNF may have a possible protective effect. It is recommended to maintain the treatment. Anti-IL-12/23, anti-integrins and tofacitinib have results comparable to anti-TNF. Based on the efficacy, expert recommendations, and the absence of other evidence, it is recommended that patients with IBD be vaccinated.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://incliva.portalinvestigacion.com/publicaciones/15798
url https://incliva.portalinvestigacion.com/publicaciones/15798
dc.language.none.fl_str_mv Español
language_invalid_str_mv Español
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER ESPANA SLU
publisher.none.fl_str_mv ELSEVIER ESPANA SLU
dc.source.none.fl_str_mv Gastroenterologia y Hepatologia
ISSN: 02105705
reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname:INCLIVA
instname_str INCLIVA
reponame_str r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418095601254400
score 15,812429

Similares en LA Referencia